Library / regulatory-reference
Finland: Finnish Medicines Agency (Fimea)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The Finnish Medicines Agency, known as Fimea, is Finland's national regulatory authority for medicines and medical devices, operating under the Ministry of Social Affairs and Health.
Finland's market sits inside the European single market, and Fimea works within the European regulatory network while overseeing a market with a strong hospital-pharmacy tradition.
How products enter the market
Medicines require marketing authorization through national or European procedures after evaluation of quality, safety and efficacy, and establishments are licensed and inspected by the agency.
Post-market work includes safety monitoring within the European alert network, and Finland's electronic prescription system gives the agency detailed visibility into medicine use.
Regional and international role
Fimea is an active member of the European regulatory network, contributing to shared assessment and safety work.
Its use of national electronic-prescription data for medicine-use research is watched by other countries building digital health infrastructure.
Using this profile
The agency publishes regulations, registers and alerts in Finnish and Swedish, with English material, through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: Finland illustrates the digitally enabled regulator: safety and use monitoring powered by national e-prescription data.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.